Beyond Air, Inc. XAIR
We take great care to ensure that the data presented and summarized in this overview for Beyond Air, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XAIR
View all-
Aigh Capital Management LLC Baltimore, MD3.71MShares$4.09 Million2.6% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$1.99 Million0.0% of portfolio
-
Gendell Jeffrey L Greenwich, CT1.46MShares$1.61 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$1.54 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.36MShares$1.49 Million0.29% of portfolio
-
Adar1 Capital Management, LLC Austin, TX1.2MShares$1.33 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY1.2MShares$1.33 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA621KShares$683,1200.0% of portfolio
-
State Street Corp Boston, MA541KShares$594,8290.0% of portfolio
-
Wealth Effects LLC409KShares$449,9000.26% of portfolio
Latest Institutional Activity in XAIR
Top Purchases
Top Sells
About XAIR
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Insider Transactions at XAIR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Douglas Quinton Larson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,048
+30.43%
|
$12,048
$1.66 P/Share
|
|
Mar 20
2024
|
Robert Carey Director |
BUY
Grant, award, or other acquisition
|
Direct |
602,410
+16.83%
|
$602,410
$1.66 P/Share
|
|
Mar 20
2024
|
Steven A. Lisi CEO and Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
78,314
+4.63%
|
$78,314
$1.66 P/Share
|
|
Dec 28
2023
|
Amir Avniel Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
13,733
-100.0%
|
$27,466
$2.05 P/Share
|
|
Dec 28
2023
|
Amir Avniel Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,267
-1.62%
|
$22,534
$2.06 P/Share
|
|
Dec 27
2023
|
Jeff Lynn Myers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,423
-6.85%
|
$6,846
$2.21 P/Share
|
|
Dec 18
2023
|
Steven A. Lisi CEO and Chairman of the Board |
BUY
Open market or private purchase
|
Direct |
77,775
+4.82%
|
$77,775
$1.63 P/Share
|
|
Dec 18
2023
|
Robert Carey Director |
BUY
Open market or private purchase
|
Direct |
1,200,000
+33.57%
|
$1,200,000
$1.64 P/Share
|
|
Nov 16
2023
|
Michael A. Gaul Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+10.19%
|
$10,000
$1.77 P/Share
|
|
Aug 28
2023
|
Robert Carey Director |
BUY
Open market or private purchase
|
Direct |
250,000
+16.95%
|
$500,000
$2.69 P/Share
|
|
Aug 21
2023
|
Robert Carey Director |
BUY
Open market or private purchase
|
Direct |
75,050
+7.15%
|
$150,100
$2.76 P/Share
|
|
Aug 18
2023
|
Robert Carey Director |
BUY
Open market or private purchase
|
Direct |
13,614
+1.49%
|
$27,228
$2.64 P/Share
|
|
Jun 30
2023
|
Michael A. Gaul Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.01%
|
$20,000
$4.51 P/Share
|
|
Mar 31
2023
|
William P Forbes Director |
BUY
Open market or private purchase
|
Direct |
5,000
+25.18%
|
$30,000
$6.67 P/Share
|
|
Mar 30
2023
|
Robert Carey Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.12%
|
$60,000
$6.45 P/Share
|
|
Mar 29
2023
|
Amir Avniel Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+25.61%
|
-
|
|
Mar 29
2023
|
Robert Carey Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.13%
|
$60,000
$6.3 P/Share
|
|
Mar 28
2023
|
Yoori Lee Director |
BUY
Open market or private purchase
|
Direct |
3,115
+19.75%
|
$18,690
$6.34 P/Share
|
|
Mar 27
2023
|
Jeff Lynn Myers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Mar 24
2023
|
Michael A. Gaul Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.35%
|
$6,000
$6.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 693K shares |
|---|---|
| Open market or private purchase | 1.63M shares |
| Open market or private sale | 28.4K shares |
|---|